Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase + Chemotherapy in Second-line Metastatic Pancreatic Cancer
NCT02195180Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Jul 2014
- Primary completion
- Feb 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of eryaspase in pancreatic adenocarcinoma (PDAC), sponsored by PHAXIAM Therapeutics. Started Jul 2014; status: completed.
02
Drugs
eryaspase
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02195180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195180.